Anti-Ganglioside GD2 Reference Antibody (Lorukafusp Alfa, RUO) (YP115026)

Name: Anti-Ganglioside GD2 Reference Antibody (Lorukafusp Alfa, RUO)
Brand: abinScience
SKU: YP115026
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	YP115026
Species reactivity	General
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Chimeric
Isotype	IgG1-kappa
Clone ID	65988-71-8
Biological activity	Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action involves enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on tumor type [1].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Ganglioside GD2
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	CAS: 65988-71-8
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	14.18 mAb, 14.18-IL-2, EMD273063, EMD 273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3
Background	Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. • Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246 • GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214 • Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230 • Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234 • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234 • Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849 • RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168 • Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas., PMID:29662203 • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881
References	1. Nazha B, et al. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. Published 2020 Jul 7. [YP115026] 2. Erber R, et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel). 2021;13(21):5577. Published 2021 Nov 8. [YP115026]
Note	For research use only. Not suitable for clinical or therapeutic use.